{
    "clinical_study": {
        "@rank": "1450", 
        "acronym": "BOX-DVT", 
        "arm_group": {
            "arm_group_label": "Rivaroxaban"
        }, 
        "brief_summary": {
            "textblock": "The objective of this NIS is to assess in a real-life setting, usage patterns and associated\n      outcomes in the management (healthcare resource utilisation and associated costs) of\n      patients with acute deep vein thrombosis treated with Xarelto, in accordance with the terms\n      of the European marketing authorization and the Belgian reimbursement criteria."
        }, 
        "brief_title": "Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Venous Thrombosis", 
        "condition_browse": {
            "mesh_term": [
                "Thrombosis", 
                "Venous Thrombosis", 
                "Venous Thromboembolism"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients with a diagnosis of deep vein thrombosis (DVT) within the past 9\n             months, enabling at least 3 months of therapy\n\n        Exclusion Criteria:\n\n          -  Patients who do not fulfil the Belgian reimbursement criteria of deep vein thrombosis\n             (DVT)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Ambulatory or hospitalized patients coming from the vascular diseases clinic of the\n        participating hospitals"
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01855100", 
            "org_study_id": "16852", 
            "secondary_id": "XA1314BE"
        }, 
        "intervention": {
            "arm_group_label": "Rivaroxaban", 
            "description": "Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.", 
            "intervention_name": "Rivaroxaban (Xarelto, BAY59-7939)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Treatment of acute deep vein thrombosis", 
            "Prevention of recurrence", 
            "Oral anticoagulation", 
            "Real-life setting"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many locations", 
                    "country": "Belgium"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "official_title": "Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto\u00ae Following an Acute Deep Vein Thrombosis (DVT)", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Real-life medical resource use consumption based on medical examination and patient diary cards", 
            "safety_issue": "No", 
            "time_frame": "Up to 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01855100"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2014"
    }
}